Reviva Pharmaceuticals Holdings, Inc.

NasdaqCM:RVPH Stock Report

Market Cap: US$83.2m

Reviva Pharmaceuticals Holdings Future Growth

Future criteria checks 0/6

Reviva Pharmaceuticals Holdings's earnings are forecast to decline at 4.9% per annum. EPS is expected to grow by 11.2% per annum.

Key information

-4.9%

Earnings growth rate

11.2%

EPS growth rate

Pharmaceuticals earnings growth22.9%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated22 Apr 2024

Recent future growth updates

Recent updates

Here's Why Reviva Pharmaceuticals Holdings (NASDAQ:RVPH) Must Use Its Cash Wisely

Aug 24
Here's Why Reviva Pharmaceuticals Holdings (NASDAQ:RVPH) Must Use Its Cash Wisely

We're Keeping An Eye On Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Dec 28
We're Keeping An Eye On Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Reviva Pharmaceuticals drops 9% on $8.5M private placement

Sep 06

We're A Little Worried About Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Aug 24
We're A Little Worried About Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Reviva Pharmaceuticals Q2 GAAP loss per share widens

Aug 15

Reviva reports positive brilaroxazine results in Aacute Schizophrenia

Apr 26

Earnings and Revenue Growth Forecasts

NasdaqCM:RVPH - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2025N/A-43N/A-583
12/31/2024N/A-43N/A-583
12/31/2023N/A-39-28-28N/A
9/30/2023N/A-38-24-24N/A
6/30/2023N/A-31-22-22N/A
3/31/2023N/A-24-21-21N/A
12/31/2022N/A-28-19-19N/A
9/30/2022N/A-20-18-18N/A
6/30/2022N/A-19-16-16N/A
3/31/2022N/A-15-14-14N/A
12/31/2021N/A-9-11-11N/A
9/30/2021N/A-6-10-10N/A
6/30/2021N/A-5-8-8N/A
3/31/2021N/A-4-7-7N/A
12/31/2020N/A-4-4-4N/A
9/30/2020N/A-2-1-1N/A
6/30/2020N/A-200N/A
3/31/2020N/A-100N/A
12/31/2019N/A-100N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RVPH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RVPH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RVPH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if RVPH's revenue is forecast to grow faster than the US market.

High Growth Revenue: RVPH is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RVPH's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.